Volume 2.35 | Sep 5

Pulmonary Cell News 2.35 September 5, 2013
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
 
TOP STORY
Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma
ACTA2 downregulation remarkably impaired in vitro migration, invasion, clonogenicity, and transendothelial penetration of lung adenocarcinoma cells without affecting proliferation. [Clin Cancer Res] Abstract
Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
Elastase Induced Lung Epithelial Cell Apoptosis and Emphysema through Placenta Growth Factor
Scientists investigated whether porcine pancreatic elastase (PPE) induces placenta growth factor (PlGF) expression, whether PlGF induces apoptosis and whether the downstream mechanisms of PlGF are related to lung epithelial cell apoptosis. They found that PPE increased PlGF secretion and expression both in vivo and in vitro. [Cell Death Dis] Full Article

Cigarette Smoke Enhances Human Rhinovirus-Induced CXCL8 Production via HuR-Mediated mRNA Stabilization in Human Airway Epithelial Cells
Primary human bronchial epithelial cells were cultured and treated with cigarette smoke extract (CSE) alone, human rhinovirus (HRV) alone or the combination of the two stimuli. Scientists showed that total expression of stabilizing/de-stabilizing proteins linked to CXCL8 regulation, including adenine/uridine-rich factor-1, KH-type splicing regulatory protein and human antigen R, are not altered by CSE, HRV or the combination of the two stimuli. [Respir Res] Abstract | Full Article

The Chitinase-Like Protein YKL-40 Increases Mucin5AC Production in Human Bronchial Epithelial Cells
Scientists explored the effect of YKL-40 on mucin5AC (MUC5AC) production in chronic inflammatory airway diseases and the potential signaling pathways involved in this process. They found that elevated YKL-40 levels increased the mRNA and protein expression of MUC5AC in a dose- and time-dependent manner, in association with the phosphorylation of extracellular signal-regulated kinase and nuclear factor ?B, reflecting their activation. [Exp Cell Res] Abstract

Effect of Apical Hyperosmotic Sodium Challenge and Amiloride on Sodium Transport in Human Bronchial Epithelial Cells from Cystic Fibrosis Donors
Hypertonic saline inhalation therapy benefits Cystic Fibrosis patients. Surprisingly, these benefits are long-lasting and are diminished by the epithelial Na+ channel blocker amiloride. Researchers aimed to explain these effects. [Am J Physiol Cell Physiol] Abstract

Rapamycin Regulates Connective Tissue Growth Factor Expression of Lung Epithelial Cells via Phosphoinositide 3-Kinase
Scientists determined the role of rapamycin in regulating epithelial cell migration and connective tissue growth factor (CTGF) expression. It was found that treatment of A549 and normal human alveolar or bronchial epithelial cells with rapamycin significantly promoted basal or transforming growth factor-ß1 induced CTGF expression. [Exp Biol Med] Abstract

Restoration of the Normal Clara Cell Phenotype after Chronic Allergic Inflammation
Bronchiolar Clara cells play a critical role in lung homoeostasis. Researchers evaluated the effects of chronic allergy on these cells and the efficacy of budesonide and montelukast in restoring their typical phenotypes after ovalbumin-induced chronic allergy in mice. [Int J Exp Pathol] Abstract

LUNG CANCER

Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Mechanistic studies demonstrated that treatment with LY2801653 inhibited the constitutive activation of MET-pathway signaling and resulted in inhibition of NCI-H441 cell proliferation, anchorage-independent growth, migration, and invasion. [Clin Cancer Res] Abstract

Pro Tumorigenic Actions of S100A2 Involves Regulation of PI3/Akt Signaling and Functional Interaction with Smad3
Investigators demonstrated that over expression of S100A2 in A549 lung cancer cells induced epithelial-mesenchymal transition followed by increased invasion, loose colony morphology in soft agar and enhanced Akt phosphorylation. [Carcinogenesis] Abstract

Cisplatin-Induced Downregulation of SOX1 Increases Drug Resistance by Activating Autophagy in Non-Small Cell Lung Cancer Cell
Scientists tested the hypothesis that cisplatin resistance is associated with alteration of SOX1 expression in non-small cell lung cancer. The level of SOX1 mRNA in cisplatin resistance cells was markedly reduced when compared to parental cells. [Biochem Biophys Res Commun] Abstract

IGF-1R/Epithelial-to-Mesenchymal Transition (EMT) Crosstalk Suppresses the Erlotinib-Sensitizing Effect of EGFR Exon 19 Deletion Mutations
Using non-small cell lung carcinoma cells harboring the erlotinib-sensitizing epidermal growth factor receptor (EGFR) exon 19 mutation delE746-A750, researchers developed erlotinib-refractory derivatives in which hyperactive insulin-like growth factor-1 receptor (IGF-1R) signaling associated with enrichment in EMT-related morphological and transcriptional features. [Sci Rep] Full Article

PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video
 
REVIEWS
LKB1/AMPK/mTOR Signaling Pathway in Non-Small-Cell Lung Cancer
In this review, the LKB1/AMPK/mTOR signaling pathway is described, highlighting its protective role, and opportunities for therapeutic intervention, and clinical trials in non-small-cell lung cancer. [Asian Pac J Cancer Prev] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
INDUSTRY NEWS
Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin®
Grifols, S.A. and Aradigm Corporation announced the closing of the transaction that includes the exclusive, worldwide license for Aradigm’s proprietary formulations of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis. [Aradigm Corporation] Press Release

Pfizer Completes Pneumococcal Pneumonia Case Accrual for CAPiTA, Adult Vaccine Clinical Trial of Prevenar 13
Pfizer Inc. announced the completion of pneumonia case accrual in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) 65 years of age and older. CAPiTA was designed to evaluate whether Prevenar 13 is effective in preventing community-acquired pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. [Pfizer Inc.] Press Release

Theravance Announces Positive Results from Phase IIb Study 0091 with Its LAMA Candidate, TD-4208, for the Treatment of COPD
Theravance, Inc. announced positive topline results from a dose-ranging 7-day cross-over design Phase IIb study of TD-4208, an investigational long-acting muscarinic antagonist (LAMA), administered once-a-day as a nebulized aqueous solution in patients with moderate to severe chronic obstructive pulmonary disease (COPD). [Theravance, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
 
POLICY NEWS
Sequester Cuts May Delay Drug Approvals – And More
The United States Congress’s current mandatory budget cuts-sequestration-threaten unprecedented opportunities in all biomedical research and development. These severe cuts raise the particular concern that translation of intricate knowledge about the molecular biology of cancer to new, targeted treatments will be impeded in part by an underfunded U.S. Food and Drug Administration. [Sci Transl Med] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Australasian Tuberculosis Conference 2013
November 28-29, 2013
Auckland, New Zealand

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Research Position – Molecular and Cellular Mechanism of Pulmonary Vascular Inflammation and Dysfunction (University of Oklahoma Health Sciences Center)

NEW Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Postdoctoral Researcher – Respiratory Diseases Research (Boehringer Ingelheim Pharma GmbH & Co. KG)

PhD (Early Stage Researcher) Position – Investigation of Mucus as a Barrier for Pulmonary Drug Delivery (Helmholtz Institute for Pharmaceutical Research Saarland)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Associate – Lung Cancer (Yale Cancer Center)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us